BASEL, Switzerland, Feb. 4 /CNW/ - Synosia Therapeutics today announced
the appointment of Philippe Lutz MA Finance, as the company's first chief
financial officer, effective immediately. He will be based at Synosia's new
headquarters in Basel, Switzerland.
Lutz joins Synosia from Credit Suisse Investment Banking where he most
recently served as a vice president of the global markets solutions group. In
a nine-year career at Credit Suisse, he contributed to a broad range of
capital market transactions and successfully completed the chartered financial
analyst exams (CFA). Lutz is a Swiss national and earned his masters in
business administration from the University of St. Gallen.
"Since Synosia started operations just over two years ago, we've
established partnerships with Roche, Novartis and Syngenta, designed and
completed our first clinical trial, prepared to start four phase II trials
later this year, and built strong teams in both San Francisco and Basel," said
the company's Chief Executive Officer and President Ian Massey.
"The establishment of our corporate headquarters in Switzerland and the
appointment of Philippe Lutz is a further step in our progression to a mature
development organization; it also underscores the importance of Switzerland as
a centre of excellence for the management, clinical development and extension
of our portfolio of compounds," Dr Massey continued.
"I knew that Synosia was the company I wanted to join once I met the
management team and saw the extraordinary progress the company has made," said
Lutz. "I was also pleased to learn of the new headquarters in Switzerland. The
strength of Switzerland's pharmaceutical sector should help sustain Synosia's
ambitious development programme."
About Synosia Therapeutics
Synosia Therapeutics develops and intends to commercialize innovative and
clinically differentiated products for unmet medical needs in psychiatry and
neurology. The privately-owned company is developing six clinical-stage
compounds acquired through key partnerships with Novartis, Roche and Syngenta.
Synosia's pipeline includes two marketed drugs that will be tested in new
indications, extending their reach into new neurological and psychiatric
diseases with high unmet medical need, including anxiety and Parkinson's
Disease. Synosia's corporate headquarters is in Basel, Switzerland.
This communication expressly or implicitly contains certain
forward-looking statements concerning Synosia Therapeutics and its business.
Such statements involve certain known and unknown risks, uncertainties and
other factors which could cause the actual results, financial condition,
performance or achievements of Synosia Therapeutics to be materially different
from any future results, performance or achievements expressed or implied by
such forward-looking statements.
Synosia Therapeutics is providing this communication as of this date and
does not undertake to update any forward-looking statements contained herein
as a result of new information, future events or otherwise.
For further information:
For further information: Synosia Therapeutics, In Europe: Julie Walters
at Tudor Reilly, Tel: +44(0)20-7016-7714, Mobile +44(0)775-3626967,
email@example.com; In US: Michele Parisi at Tudor Reilly, Tel: